SCHEMBL225077

SCHEMBL225077

Cc1cc(C)c(C(=O)[PH](=O)OCCc2ccccc2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
ADAM17 P78536 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
ALOX5 P09917 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
USP2 O75604 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
TTR P02766 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7086681 0.92 NPC1 (0.42) GAANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7188493 0.78 L3MBTL1 (0.41) GAAL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL338678 0.78 BRD4 (0.40) L3MBTL1SMN1; SMN2MEN1KMT2AATM
SCHEMBL28983948 0.77 L3MBTL1 (0.42) GAAL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL28034480 0.77 ITGB1 (0.39) MMP9MMP13ADAM17NPC1RAB9A
SCHEMBL7183325 0.76 CYP2C9 (0.38) GAANPC1RAB9AMEN1KMT2A
SCHEMBL3109009 0.76 TACR1 (0.39) L3MBTL1MEN1KMT2AKDM4EPOLB
SCHEMBL7182295 0.76 SMN1; SMN2 (0.45) GAAL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL6374832 0.76 SMN1; SMN2 (0.38) L3MBTL1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL7182701 0.75 SMN1; SMN2 (0.44) GAAL3MBTL1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024263142-A1 HEXADECYL ACRYLATE-BASED PHOTO-CURABLE RESINS FOR 4D PRINTING OF BODY TEMPERATURE RESPONSIVE HYDROGELS WITH SHAPE MEMORY AND SELF-HEALING PROPERTIES ISTANBUL TEKNIK UNIVERSITESI (TR) 2024-12-26 WO claimed
US-10179445-B2 Method for producing optical member and use of ultraviolet ray cured resin composition for same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2019-01-15 US claimed
US-20170198076-A1 CURABLE COMPOSITION AND POLYMER MITSUBISHI RAYON CO., LTD. (JP) 2017-07-13 US claimed
US-9663603-B2 Curable composition and polymer MITSUBISHI RAYON CO., LTD. (JP) 2017-05-30 US claimed
EP-2769997-B1 METHOD FOR PRODUCING OPTICAL MEMBER AND USE OF ULTRAVIOLET RAY CURED RESIN COMPOSITION FOR SAME NIPPONKAYAKU KK (JP) 2017-04-26 EP claimed
US-20150224756-A1 Method For Producing Optical Member And Use Of Ultraviolet Ray Cured Resin Composition For Same NIPPON KAYAKU KK (JP) 2015-08-13 US claimed
US-20140248498-A1 Method For Producing Optical Member And Use Of Ultraviolet Ray Cured Resin Composition For Same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-09-04 US claimed
EP-2769997-A1 METHOD FOR PRODUCING OPTICAL MEMBER AND USE OF ULTRAVIOLET RAY CURED RESIN COMPOSITION FOR SAME Nipponkayaku Kabushikikaisha (JP) 2014-08-27 EP claimed
US-20050142292-A1 rotogravure printing inks, whose polymerization is initiated by actinic radiation; printing ink contains as vinyl ether monomeric vinyl ethers or hydroxyvinyl ethers FLINT INK CORPORATION (US) 2005-06-30 US claimed
EP-1442088-B1 GRAVURE PRINTING PROCESS USING FREE RADICAL CURABLE PRINTING INKS SCHMIDT GEBR DRUCKFARBEN (DE) 2005-06-01 EP claimed
US-6756420-B2 HIGH-SOLIDS COATING COMPOSITION WHICH COMPRISES (A) A COMPOUND WHICH HAS AT LEAST ONE RADICALLY POLYMERIZABLE UNSATURATED GROUP PER MOLECULE, (B) A HYDROXYL GROUP-CONTAINING ESTER COMPOUND WHICH IS OBTAINED BY ESTER-FORMING ADDITION REACTION KANSAI PAINT CO., LTD. (JP) 2004-06-29 US claimed
US-20030119980-A1 Coating composition and a process to form a coating film with use thereof KANSAI PAINT CO., LTD. (JP) 2003-06-26 US claimed
US-12637531-B2 Pigment dispersant composition, production method therefor, pigment dispersion, and actinic-ray-curable ink-jet ink DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) 2026-05-26 US disclosed
EP-4738390-A1 TRANSPARENT CONDUCTIVE FILM Nitto Denko Corporation (JP) 2026-05-06 EP disclosed
US-12601971-B2 Negative photosensitive resin composition ZEON CORPORATION (JP) 2026-04-14 US disclosed
US-20260092180-A1 PHOTOCURABLE COATING COMPOSITION AND COATED ARTICLE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-04-02 US disclosed
US-5679863-A Preparation of carbonylphosphine oxides BASF AKTIENGESELLSCHAFT (DE) 1997-10-21 US disclosed
US-5504236-A Preparation of α-carbonylphosphine oxides BASF AKTIENGESELLSCHAFT (DE) 1996-04-02 US disclosed
US-4985472-A ACRYLATED POLYISOCYANATE MITSUBISHI RAYON COMPANY, LTD. (JP) 1991-01-15 US disclosed
EP-0313665-A1 ACTINIC RADIATION-CURABLE COMPOSITION FOR CAST POLYMERIZATION AND PRODUCT OF CAST POLYMERIZATION MITSUBISHI RAYON CO., LTD. (JP) 1989-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637531-B2 Pigment dispersant composition, production method therefor, pigment dispersion, and actinic-ray-curable ink-jet ink VCL, DYNLL1, DYNLL2 GAA 2002/4885MMP1 1163/4885MMP9 3434/4885
US-20260092180-A1 PHOTOCURABLE COATING COMPOSITION AND COATED ARTICLE COL1A1, COL2A1, HBS1L GAA 2207/4885MMP1 520/4885MMP9 1042/4885
US-12601971-B2 Negative photosensitive resin composition ARCN1, RAD51, RER1 GAA 1819/4885MMP1 4186/4885MMP9 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.